What Is the Role of AI in Liquid Biopsy Analysis?

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: July 31, 2022 | Precision Medicine and Genomics

DOI: 10.5281/zenodo.17998519

Abstract

Liquid biopsy is a groundbreaking, non-invasive technique for detecting and monitoring cancer by analyzing biomarkers in bodily fluids like blood. This metho...

What Is the Role of AI in Liquid Biopsy Analysis?

By Rasit Dinc

Liquid biopsy is a groundbreaking, non-invasive technique for detecting and monitoring cancer by analyzing biomarkers in bodily fluids like blood. This method offers a significant advantage over traditional tissue biopsies, which are often invasive and not always feasible. The integration of artificial intelligence (AI) into liquid biopsy analysis has opened up new possibilities in precision medicine, greatly improving our ability to detect cancer early, personalize treatments, and monitor disease progression with high accuracy. This article explores the crucial role of AI in liquid biopsy and its transformative impact on oncology.

Enhancing Diagnostic Accuracy with AI

A major challenge in liquid biopsy is the low concentration of cancer biomarkers, such as circulating tumor DNA (ctDNA), in early-stage disease. AI, with its powerful machine learning and deep learning algorithms, is well-equipped to handle this issue. These algorithms can analyze vast and complex datasets to identify subtle patterns that may be missed by conventional methods. By examining genomic, epigenomic, and proteomic data, AI can detect the faint signals of cancer with high sensitivity and specificity [1].

AI models like Support Vector Machines (SVMs) and Random Forests are used to classify tumors, while deep learning models such as Convolutional Neural Networks (CNNs) can learn complex patterns from sequencing data. Studies have shown that AI-driven analysis of cfDNA methylation and fragmentation patterns can accurately detect various cancers, including lung and gastrointestinal malignancies, at very early stages [1, 2]. By integrating data from multiple sources, AI-powered platforms can provide a more comprehensive and accurate diagnosis, reducing the chances of false negatives and enabling earlier intervention.

Enabling Personalized Treatment and Real-Time Monitoring

The benefits of AI-enhanced liquid biopsy go beyond diagnosis. It is a key component of personalized medicine, enabling the selection of treatments tailored to the unique molecular profile of a patient's tumor. A simple blood draw can provide a comprehensive genomic and transcriptomic profile of the cancer. AI algorithms can then analyze this data to identify specific driver mutations and actionable biomarkers. The Caris Assure platform, for example, uses whole exome and transcriptome sequencing with machine learning to provide therapy recommendations that are highly consistent with traditional tissue-based testing [3].

Furthermore, AI-powered liquid biopsy allows for real-time monitoring of treatment response and disease evolution. By tracking the levels of ctDNA and other biomarkers over time, clinicians can gain insights into how a tumor is responding to therapy. This allows for the early detection of treatment failure or the emergence of drug resistance, enabling prompt adjustments to the therapeutic strategy. This continuous feedback is invaluable for optimizing patient outcomes and minimizing exposure to ineffective treatments.

The Future of AI in Liquid Biopsy: Promise and Challenges

The synergy between AI and liquid biopsy is a rapidly developing field with the potential to reshape oncology. The integration of AI with other diagnostic tools, such as radiomics, which involves extracting quantitative features from medical images, is a promising area of research. By combining molecular data from liquid biopsies with spatial information from imaging, AI can create a more complete picture of the tumor and its microenvironment [1]. This multi-modal approach is expected to lead to even more accurate diagnostic and prognostic models.

Despite the significant progress, several challenges need to be addressed. The standardization of data acquisition and processing is crucial for ensuring the reproducibility of results. The development of large, well-annotated datasets is also essential for training robust AI models. Additionally, the interpretability of some complex AI models can be a barrier to clinical adoption. Efforts are ongoing to develop more transparent and explainable AI methods.

In conclusion, the integration of AI into liquid biopsy analysis is a transformative development in oncology. It is improving our ability to detect cancer earlier, personalize treatment more effectively, and monitor disease progression in real-time. While challenges remain, the continued advancement of AI and liquid biopsy technologies promises a future where cancer is managed as a dynamic and individualized disease, leading to better outcomes for patients worldwide.

References

[1] Cherukuri, S. P., et al. (2025). Artificial Intelligence-Enhanced Liquid

Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm. *Cancers (Basel)*, *17*(19), 3165. https://pmc.ncbi.nlm.nih.gov/articles/PMC12524159/

[2] Hussain, M. S., et al. (2025). AI-powered liquid biopsy for early detection of gastrointestinal cancers. *Clinica Chimica Acta*, *577*, 120484. https://www.sciencedirect.com/science/article/abs/pii/S0009898125003638

[3] Abraham, J., et al. (2025). Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. *Scientific Reports*, *15*(1), 8986. https://www.nature.com/articles/s41598-025-08986-0
